BOC "near deal" on sale of Ohmeda:
This article was originally published in Clinica
Executive Summary
UK company BOC has confirmed it is at an advanced stage in negotiations to sell its Ohmeda healthcare division. However, it refused to comment on whether the purchaser is US company Abbott Laboratories as press reports have suggested. The price is reportedly expected to be £750 million ($1.2 billion), somewhat less than the £1 billion price tag which had been mentioned earlier. Ohmeda businesses include anaesthetics and critical care pharmaceuticals, anaesthesia delivery and patient monitoring systems. The division's profits have been declining since 1992 when it lost the patent on the anaesthetic Forane.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.